mRNA redesigned medicine redefined
Kernal's synthetic biology-based approach includes the development of a platform using deep learning algorithms and big data to create better designed mRNAs.
Smart engineering makes our mRNAs selective for cancer cells, they have no expression in healthy cells.
Our proprietary design and manufacturing processes enable the evasion of RNA sensors, particularly for repetitive applications.
Kernal Biologics is an award-winning startup developing cancer cell-specific immunotherapy. Kernal Biologics was founded by four young scientists. Together, we bring a broad range of experience from synthetic biology, immuno-oncology, and deep learning.
Our vision is to develop curative immunotherapies for cancers with high unmet medical need by using deep learning and synthetic biology.
Thanks to our unique methods of codon-engineering and smart design, our proprietary platform decreases immunogenicity upon existing mRNA technologies and enables cell-specific therapeutic protein expression. This allows us to design and develop more efficacious, tolerable, and affordable medicine for the global market.